PIC1 Injection Therapy for Relapsed/Refractory B-NHL
This is an investigator-initiated trial aimed at assessing the safety and efficacy of PIC1 injection in the treatment of relapsed/refractory B-cell Non-Hodgkin Lymphoma.
| Condition(s) | Non-Hodgkin Lymphoma |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | This is an investigator-initiated trial aimed at assessing the safety and efficacy of PIC1 injection in the treatment of relapsed/refractory B-cell Non-Hodgkin Lymphoma. |
| Who can participate | Inclusion Criteria: * The patient (or their legally authorized representative) has voluntarily agreed to participate in this clinical trial and has signed the Informed Consent Form (ICF), indicating full understanding of the study's objectives and procedures. * Aged 18 to 75 years, regardless of gender. * Histologically or cytologically confirmed B-cell Non-Hodgkin Lymphoma (NHL) according to the WHO 2017 classification, including the following subtypes: 1. Diffuse Large B-Cell Lymphoma (DLBCL): Including DLBCL, not otherwise specified (DLBCL, NOS); DLBCL associated with chronic inflammation; Primary Cutaneous DLBCL, leg type; and EBV-positive DLBCL, NOS. 2. High-Grade B-Cell Lymphoma (HGBL): Including HGBL, NOS; and HGBL with MYC and BCL2 and/or BCL6 rearrangements. 3. Primary Mediastinal |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Chongqing Precision Biotech Co., Ltd |
| Locations | Wuhan, Hubei, China |
| Start date | 2026-03 |
| NCT ID | NCT07456371 |
| Official listing | https://clinicaltrials.gov/study/NCT07456371 |